|Last Price$7.16||Day Change (%)0.56%|
|Open Price$7.12||Day Change ($)0.04|
|Day Range7.11–7.30||52-Week Range3.05–13.26|
As of Fri 3/27/2015 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Research and Markets: Intermittent Claudication Pipeline Review 2015 - 9 Companies & 11 Drug Profiles
Research and Markets: Myasthenia Gravis Therapeutics Pipeline Review H1 2015
Cytokinetics faces challenging odds.